

## SAFETY DATA SHEET

### SECTION 1 : IDENTIFICATION

**Product Name:** **Topotecan Hydrochloride for Injection, USP**  
**Product Use/Restriction:** Antineoplastic.  
**Manufacturer Name:** Fresenius Kabi USA, LLC  
**Address:** Three Corporate Drive  
 Lake Zurich, Illinois 60047  
**General Phone Number:** (847) 550-2300  
**Customer Service Phone Number:** (888) 386-1300  
**Health Issues Information:** (800) 551-7176  
**SDS Creation Date:** November 30, 2010  
**SDS Revision Date:** November 21, 2017  
**(M)SDS Format:**

### SECTION 2 : HAZARD(S) IDENTIFICATION

**GHS Class:** Reproductive toxicity. Effects on or via lactation.  
**Hazard Statements:** May cause harm to breast-fed children.  
**Precautionary Statements:** Obtain special instructions before use.  
 Do not breathe dust/fume/gas/mist/vapours/spray.  
 Avoid contact during pregnancy and while nursing.  
 Wash hands thoroughly after handling.  
 Do not eat, drink or smoke when using this product.  
 IF exposed or concerned: Get medical advice/attention.

**Emergency Overview:** This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Avoid contact with skin, eyes, nostrils and mouth.

**Route of Exposure:** Inhalation Ingestion Eye contact Skin Absorption. Injection.

**Potential Health Effects:** Caution - Potent pharmaceutical agent. May cause cancer. May produce adverse effects on the development of human offspring. Possible effects of overexposure in the workplace include: nausea; vomiting; diarrhoea; bone marrow toxicity.

**Eye:** Contact with eyes may cause irritation.  
**Skin:** May cause irritation.  
**Inhalation:** May cause irritation.  
**Ingestion:** May be harmful if ingested.

**Signs/Symptoms:** Overexposure in the workplace might have the following effects: reduced white blood cell count; nausea; diarrhoea; vomiting; fatigue.

**Target Organs:** bone marrow and formation of blood cells

**Aggravation of Pre-Existing Conditions:** None generally recognized.

### SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Topotecan	119413-54-6	4 mg/vial	
Mannitol	69-65-8	48 mg/vial	
Tartaric Acid	87-69-4	20 mg/vial	

### SECTION 4 : FIRST AID MEASURES

**Eye Contact:** Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.

**Skin Contact:** Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.

**Inhalation:** If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained

personnel. Seek immediate medical attention.

**Ingestion:** If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

**Other First Aid:** For Adverse Event Information, please call (800) 551-7176.

## SECTION 5 : FIRE FIGHTING MEASURES

**Flash Point:** Not established.

**Flash Point Method:** Not established.

**Auto Ignition Temperature:** Not established.

**Lower Flammable/Explosive Limit:** Not established.

**Upper Flammable/Explosive Limit:** Not established.

**Fire Fighting Instructions:** Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.

**Extinguishing Media:** Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**Protective Equipment:** As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.

**Hazardous Combustion Byproducts:** Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

## SECTION 6 : ACCIDENTAL RELEASE MEASURES

**Personal Precautions:** Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.

**Environmental Precautions:** Avoid runoff into storm sewers, ditches, and waterways.

**Methods for containment:** Contain spills with an inert absorbent material such as soil, sand or oil dry.

**Methods for cleanup:** Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

## SECTION 7 : HANDLING and STORAGE

**Handling:** When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.

**Storage:** Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light; product is light-sensitive. Retain in carton.

**Work Practices:** Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.

**Hygiene Practices:** Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

## SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

**Engineering Controls:** General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.

**Eye/Face Protection:** Chemical splash goggles. Wear a face shield also when splash hazard exist.

**Skin Protection Description:** Protective laboratory coat, apron, or disposable garment recommended.

**Hand Protection Description:** Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

**Respiratory Protection:** No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (<http://www.cdc.gov/niosh/nppt/topics/respirators/>) for a list of respirator types and approved suppliers.

**Other Protective:** Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

### EXPOSURE GUIDELINES

#### **Tartaric Acid :**

**Guideline ACGIH:** Not established.

Guideline OSHA: Not established.  
British Columbia Canada : Not established.

## SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State: Lyophilized powder.  
Color: White to pale yellow.  
Boiling Point: Not established.  
Melting Point: Not established.  
Solubility: Soluble. in water.  
Vapor Density: Not established.  
Vapor Pressure: Not established.  
Percent Volatile: Not established.  
pH: 2.5-3.5 (reconstituted.)  
Molecular Formula: Mixture  
Molecular Weight: 182.19  
Flash Point: Not established.  
Flash Point Method: Not established.  
Auto Ignition Temperature: Not established.

## SECTION 10 : STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.  
Hazardous Polymerization: Not reported.  
Conditions to Avoid: Protect from light.  
Incompatible Materials: Avoid contact with oxidizing agents.

## SECTION 11 : TOXICOLOGICAL INFORMATION

### Topotecan :

RTECS Number: UQ0491400  
Ingestion: Oral - Mouse TDLo: 40 mg/kg/21D (Intermittent) [Tumorigenic - Active as anti-cancer agent]  
Other Toxicological Information: Intravenous. - Mouse TDLo: 7.5 mg/kg/3D (intermittent) [Tumorigenic - Protects against induction of experimental tumors]  
Intraperitoneal. - Mouse TDLo: 5.4 mg/kg/3D (intermittent) [Blood - changes in bone marrow (not otherwise specified)]

### Mannitol :

RTECS Number: OP2060000  
Ingestion: Oral - Rat LD50: 13500 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Oral - Mouse LD50: 22 gm/kg [Behavioral - Somnolence (general depressed activity); Gastrointestinal - Ulceration or bleeding from small intestine]  
Other Toxicological Information: Intravenous. - Rat LD50: 9690 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Mouse LD50: 7470 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intraperitoneal. - Mouse LD50: 14 gm/kg [Details of toxic effects not reported other than lethal dose value]

### Tartaric Acid :

RTECS Number: WW7875000  
Ingestion: Oral - Rat LDLo: 7500 mg/kg [Lungs, Thorax, or Respiration - Other changes; Gastrointestinal - Other changes]  
Oral - Rabbit LDLo: 5 gm/kg [Behavioral - Somnolence (general depressed activity)]  
Other Toxicological Information: Intravenous. - Mouse LD50: 485 mg/kg [Behavioral - Convulsions or effect on seizure threshold; Blood - Hemorrhage] (RTECS)

## SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.  
Environmental Stability: No environmental information found for this product.

## SECTION 13 : DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

---

## SECTION 14 : TRANSPORT INFORMATION

---

DOT Shipping Name: Medicine, solid, toxic, n.o.s.  
DOT UN Number: UN3249  
DOT Hazard Class: 6.1  
DOT Packing Group: III  
DOT Exemption: ORM-D Consumer Commodity.  
Quantities equal to or less than 0.25 kg per inner packaging are not subject to the full packaging and labelling requirements

---

## SECTION 15 : REGULATORY INFORMATION

---

### Mannitol:

TSCA Inventory Status: Listed  
EINECS Number: 200-711-8  
Canada DSL: Listed

### Tartaric Acid:

TSCA Inventory Status: Listed  
Canada DSL: Listed

---

## SECTION 16 : ADDITIONAL INFORMATION

---

### HMIS Ratings:

SDS Creation Date: November 30, 2010  
SDS Revision Date: November 21, 2017  
SDS Format:

### Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.